Teknova Announces Pricing of $40 Million Public Offering of Common Stock

The financing adds common shares, with an underwriter option allowing up to 1,200,000 additional shares.

Rhea-AI Summary

Alpha Teknova (Nasdaq: TKNO) priced an underwritten public offering of its common stock expected to raise $40 million in gross proceeds.

The offering comprises 8,000,000 shares at $5.00 each, all sold by Teknova. Expected gross proceeds exclude underwriting discounts, commissions and offering expenses. Underwriters have a 30-day option to purchase up to 1,200,000 additional shares. The company expects closing on or about October 22, 2026, subject to customary closing conditions. Teknova intends to use net proceeds for general corporate purposes, potentially including repayment of outstanding debt obligations.

2 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Offering expected to raise $40 million in gross proceeds before underwriting discounts, commissions and offering expenses. 11% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Teknova intends net proceeds for general corporate purposes, potentially including repayment of outstanding debt obligations.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.8,000,000 new common shares at $5.00 each will dilute existing shareholders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Underwriters’ 30-day option for up to 1,200,000 additional shares could add further dilution.

News Explained

The offering is priced but has not closed; if completed, Teknova’s sale of 8 million common shares will increase the total share count and reduce existing holders’ percentage ownership.

Key Figures

Offering shares: 8,000,000 shares Public offering price: $5.00 per share Expected gross proceeds: $40 million +2 more

Offering shares

8,000,000 shares

Shares of common stock in the public offering

Public offering price

$5.00 per share

Price to the public

Expected gross proceeds

$40 million

Before underwriting discounts, commissions, and offering expenses

Underwriters' option

Up to 1,200,000 additional shares

30-day option to purchase common stock

Expected closing

October 22, 2026

On or about this date, subject to customary closing conditions

Historical Context

1 past event · Latest: Aug 05

1 event

1. Aug 05

   Q2 earnings

   24h Move

   +16.4%

   Reported $17.4 million in cash and investments and $13.2 million borrowings, informing potential debt repayment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, shelf registration statement, prospectus supplement

3 terms

underwritten public offering financial

"pricing of its underwritten public offering of 8,000,000 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement and the accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of common stock in the offering are to be sold by Teknova. The offering is expected to close on or about October 22, 2026, subject to the satisfaction of customary closing conditions.

TD Cowen and William Blair are acting as joint book-running managers for the proposed offering. Craig-Hallum is acting as lead manager. Stephens Inc. and Roth Capital Partners are acting as co-managers. Perrella Weinberg Partners is serving as financial adviser to Teknova.

Teknova currently intends to use the net proceeds from this offering for general corporate purposes, including potentially the repayment of outstanding debt obligations. Teknova may use a portion of the net proceeds to acquire or invest in other businesses, products, and technologies that are complementary to its own, although Teknova has no current commitments or arrangements to do so.

The public offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-288613), previously filed with the Securities and Exchange Commission (the “SEC”) on July 10, 2025, and declared effective on July 16, 2025. The securities may be offered only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering, may also be obtained by contacting TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at TDManualrequest@broadridge.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at 1-800-621-0687, or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Teknova

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Teknova’s expectations on the timing and completion of the offering and the anticipated use of proceeds therefrom. Forward-looking statements can often be identified by such words as "will," "expects," "plans," "believes," "intends," "estimates," "projects," "continue," "potential" or other similar words or expressions. Forward-looking statements are based on Teknova's current expectations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market and other conditions and the satisfaction of customary closing conditions related to the proposed public offering and other risks that are described in Teknova’s most recent periodic reports filed with the Securities and Exchange Commission, including Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Teknova disclaims any obligation to update these forward-looking statements, except as required by applicable law.

Contacts:

Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100

Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259

This press release was published by a CLEAR® Verified individual.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Teknova raising in its TKNO stock offering, and at what price?

Teknova expects $40 million in gross proceeds from selling 8,000,000 common shares at $5.00 per share. That amount is before underwriting discounts, commissions and offering expenses. All shares in the offering are being sold by Teknova.

When is Teknova's public stock offering expected to close?

Teknova expects the offering to close on or about October 22, 2026, subject to satisfaction of customary closing conditions.

Could Teknova use the offering proceeds for acquisitions?

Teknova may use a portion of net proceeds to acquire or invest in complementary businesses, products and technologies. The company has no current commitments or arrangements to do so.